Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Delcath Systems Inc (DCTH)

Delcath Systems Inc (DCTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma Business Wire - Wed Dec 3, 3:01PM CST

Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication...

DCTH : 9.88 (+2.49%)
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program Business Wire - Thu Nov 20, 3:01PM CST

Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath”) an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors...

DCTH : 9.88 (+2.49%)
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma Business Wire - Tue Nov 18, 7:00AM CST

Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication...

DCTH : 9.88 (+2.49%)
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Nov 14, 3:01PM CST

Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the...

DCTH : 9.88 (+2.49%)
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients Business Wire - Thu Nov 13, 7:30AM CST

Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication...

DCTH : 9.88 (+2.49%)
Delcath Systems to Participate in Upcoming Investor Conferences Business Wire - Thu Nov 6, 3:01PM CST

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following...

DCTH : 9.88 (+2.49%)
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights Business Wire - Tue Nov 4, 7:00AM CST

Conference Call Today at 8:30 a.m. Eastern Time

DCTH : 9.88 (+2.49%)
Delcath Systems to Host Third Quarter 2025 Earnings Call Business Wire - Tue Oct 21, 7:30AM CDT

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November...

DCTH : 9.88 (+2.49%)
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results Business Wire - Sat Oct 18, 3:15PM CDT

Conference Call October 20, 8:45am EST

DCTH : 9.88 (+2.49%)
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint Business Wire - Sat Oct 18, 3:13PM CDT

Conference Call October 20, 8:45am EST

DCTH : 9.88 (+2.49%)

Barchart Exclusives

Is Cotton a Buy Before the End of 2025? Barchart - 22 minutes ago
Nearby ICE cotton futures have not traded above 70 cents per pound since May 2025, but they have also remained above 60 cents. With the cotton market in the heart of winter, it could be the perfect time to consider a long position in the fluffy fiber for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot